Work at Avioris Bio Inc. has led to the discovery of proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors reported to be useful for the treatment of hypercholesterolemia.
Foshan Ionova Biotherapeutics Co. Ltd., Guangdong Touchstone Translational Research Institute Co. Ltd. and Shenzhen Ionova Life Science Co. Ltd. have synthesized new interleukin-17A (IL-17A) inhibitors described as potentially useful for the treatment of inflammatory disorders.
Zhejiang Pantheon Innovation Pharmaceutical Co. Ltd. has disclosed prodrugs of an NLRP3 inflammasome inhibitor compound. They are reported to be useful for the treatment of cancer and inflammation.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have discovered GTPase KRAS mutant inhibitors, particularly G12V, G12D and G12C mutant inhibitors. They are reported to be useful for the treatment of cancer.
Children’s Medical Center Corp. has synthesized ceramide glucosyltransferase (glucosylceramide synthase; GLCT-1) inhibitors with potential for use in the treatment of cancer, neurological disorders, infections and more.
Humanwell Healthcare (Group) Co. Ltd. has divulged molecular glue degraders comprising cereblon (CRBN)-binding agents acting as proto-oncogene Vav (VAV1) degradation inducers. They are reported to be useful for the treatment of autoimmune disease, cancer, inflammatory bowel disease, multiple sclerosis, myasthenia gravis, periodontitis, psoriasis, rheumatoid arthritis and type I diabetes, among others.
Synnovation Therapeutics Inc. has reported Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
RSS